ADC Therapeutics (ADCT) Current Assets (2019 - 2026)

ADC Therapeutics has disclosed Current Assets across 8 years of filings, most recently posting $261.7 million for Q2 2026.

• In Q2 2026, Current Assets fell 17.9% year-over-year to $261.7 million; the TTM figure through Jun 2026 stood at $261.7 million (down 17.9% YoY), while the FY2025 annual figure was $306.3 million, up 5.18% from the prior year.
• Current Assets came in at $261.7 million for Q2 2026 at ADC Therapeutics, down from $276.8 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $487.7 million in Q1 2022 to a low of $258.0 million in Q1 2025.
• Average Current Assets over 5 years is $348.2 million, with a median of $334.6 million recorded in 2023.
• Year-over-year, Current Assets advanced 24.02% in 2022 and retreated 23.63% in 2024.
• Over 5 years, Current Assets stood at $435.0 million in 2022, then fell by 22.69% to $336.3 million in 2023, then fell by 13.39% to $291.3 million in 2024, then gained by 5.18% to $306.3 million in 2025, then dropped by 14.57% to $261.7 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $261.7 million in Q2 2026, $276.8 million in Q1 2026, and $306.3 million in Q4 2025.